心血管

订阅

MedSci主页 / 所有栏目 / 心血管

NEJM：依折麦布联合他汀类药物降胆固醇可降低心血管事件风险(IMPROVE-IT研究)

2015-08-20 MedSci MedSci原创

依折麦布胆固醇
关注

《新英格兰医学杂志》日前发表一项历时10年的名为《进一步降低终点事件：葆至能(依折麦布/辛伐他汀片)疗效国际试验》(IMPROVE-IT)的论文，该研究首次证实非他汀类药物降胆固醇治疗也可降低心血管事件风险。此前也有类似报道：IMPROVE-IT研究：降胆固醇是“硬道理” IMPROVE-IT是一项国际性、多中心、随机、双盲、活性对照组试验，由来自美国、英国、加拿大等30多个国家的研

《新英格兰医学杂志》日前发表一项历时10年的名为《进一步降低终点事件：葆至能(依折麦布/辛伐他汀片)疗效国际试验》(IMPROVE-IT)的论文，该研究首次证实非他汀类药物降胆固醇治疗也可降低心血管事件风险。此前也有类似报道：IMPROVE-IT研究：降胆固醇是“硬道理”
 

IMPROVE-IT是一项国际性、多中心、随机、双盲、活性对照组试验，由来自美国、英国、加拿大等30多个国家的研究机构共同完成，共入组18144名急性冠脉综合征高危患者。该研究旨在探索非他汀类药物依折麦布联合他汀类药物把低密度脂蛋白胆固醇降至70 mg/dl以下时是否会进一步减少心血管事件的发生。结果显示：相较于辛伐他汀单药治疗，辛伐他汀联合依折麦布可显著减少高危患者严重心血管事件的发生 。

他汀单药治疗、依折麦布/他汀联合治疗显著降低LDL-C，从而显著减少心血管终点事件。那么，他汀类药物，或依折麦布联合他汀类治疗带来的心血管获益是源于其降LDL-C的作用，还是某种药物独特的作用(降脂外作用)?2012年发表的孟德尔随机对照研究分析了312321例患者长期暴露于低LDL-C相关6个基因的9个多态性的冠心病风险，由基因多态性导致的LDL-C每降低1mmol/L，冠心病风险下降54.5%，显著优于他汀治疗LDL-C每降低1mmol/L，冠心病风险下降21%，首次从遗传学角度阐述了LDL-C与心血管病的关系。2014年发表的研究显示，单独携带NPC1L1(依折麦布作用靶点)、或HMG辅酶A还原酶(他汀作用靶点)基因多态性导致的低LDL-C状态与冠心病风险降低呈线性关系，携带双基因多态性者冠心病风险下降具有累加效应，从遗传学角度支持他汀联合依折麦布降低LDL-C、进一步降低心血管事件的研究结果，充分说明能够降低胆固醇水平的治疗即可减少心血管事件风险。

ASCVD二级预防，LDL-C是否低一些更好?他汀问世的20年间，其研究一再将LDL-C推向更低的水平，无论从心血管获益还是安全性方面，一再地证明了“低一些更好”的理念。胆固醇治疗研究者协作组(CTT)荟萃分析26项以心血管事件为终点的他汀研究，结果显示，无论基线LDL-C水平如何，只要降低1mmol/L的LDL-C，就可以带来21%的心血管获益。其中PROVE-IT研究表明，LDL-C在62mg/dl以上的范围内与心血管获益仍呈线性相关关系。

如果继续降低LDL-C水平可否继续保持与心血管获益的线性关系，还是像血压和血糖一样存在“J”型曲线是降脂领域中的关注焦点。IMPROVE-IT研究中LDL-C达到54mg/dl仍然可以在ASCVD的二级预防上获益。同时，并未因进一步降低LDL-C出现不良反应的增加，为未来开发新型降胆固醇药物、进一步降低LDL-C治疗的安全性奠定了基础。

如何选择ASCVD二级预防的优化策略级预防的优化策略??近年血脂异常防治威廉亚洲博彩公司 (建议)中防治ASCVD的LDL-C目标水平趋于更低。更严格的LDL-C管理需要更为有效且安全的降脂方案。他汀作为抗动脉粥样硬化治疗的基石无可撼动。然而，近期DYSIS-China研究显示，接受他汀治疗的总体达标率为61.5%，而冠心病患者的达标率仅44.1%。他汀治疗剂量倍增带来LDL-C水平的进一步降幅仅为6%，而剂量倍增，特别是高剂量他汀可能带来安全性和耐受性的问题。IMPROVE-IT研究印证了他汀加用依折麦布降胆固醇的增效作用。对于常规他汀剂量治疗LDL-C未能达标的ASCVD患者，依折麦布联合他汀是未来降脂治疗的优化选择。

Q江苏省人民医院王向明医师：IMPROVE-IT研究中主要转归终点事件只计入随机分组后的首次事件，其后发生的心血管事件不纳入结果分析。因此，本研究中两组各有42%的受试者在研究结束前停止试验用药，这对研究结果的可靠性是否有影响?

该研究的对象为急性冠脉综合征(ACS)患者;其结论能否推论到稳定性心绞痛或高LDL-C水平合并存在心血管极高风险的人群中，个人认为值得商榷。请问专家怎么看?

A上海交通大学医学院附属瑞金医院陆国平教授：IMPROVE-IT研究的循证医学价值是第一次证实了LDL-C<70mg/dl的患者应用他汀降低LDL-C仍可获益;其临床指导价值是，就目前而言，ASCVD二级预防LDL-C54mg/dl这A一值可能是降胆固醇最大获益的阈值。

只计入随机分组后的首次发作事件对研究可靠性没有影响，理由如下：①已知的大多数他汀临床研究均是比较分组后的两组首发事件的发生率，但随访至研究结束。②有研究表明，如果首发事件降低，其后的事件发生率也是降低的，而且降低幅度更大，例如TNT研究。

IMPROVE-IT研究结论能否推论至稳定性心绞痛?我的回答也是“值得商榷”。是否所有的ACS患者/所有的稳定性心绞痛患者均需把LDL-C降低至53或54mg/dl，更值得商榷!

如果ACS或稳定性心绞痛患者属高龄，或伴糖尿病，或无出血性卒中史，其LDL-C降至53或54mg/dl可进一步获益。反之，年龄小于65岁、无糖尿病的ACS患者或不稳定性心绞痛患者，其LDL-C降至(或接近)70mg/dl即可，有出血性卒中史的患者更是如此。

原始出处：

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. 

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-01-27 hukaixun

    #血管事件#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-05-28 tcm109hq

    #IMPROVE-IT研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-06-05 ms6390871039024434

    #他汀类药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-01-27 doctording1

    这篇文章有一定深度

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-01-27 doctording1

    值得临床关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-01-27 doctording1

    是一篇不错的文章

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2016-01-27 doctording1

    不错，赞一个

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    好学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2015-12-15 yuwenpsy

    ……

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1643366, encodeId=906d1643366c9, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jan 27 16:04:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699672, encodeId=f07316996e2ab, content=<a href='/topic/show?id=f626980156' target=_blank style='color:#2F92EE;'>#IMPROVE-IT研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9801, encryptionId=f626980156, topicName=IMPROVE-IT研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=998729968932, createdName=tcm109hq, createdTime=Sat May 28 13:04:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044379, encodeId=17b520443e93c, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jun 05 09:04:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60718, encodeId=c11860e18d3, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60721, encodeId=11d960e213e, content=值得临床关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60719, encodeId=abfe60e19e3, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60717, encodeId=681a60e17a7, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:45:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49587, encodeId=07884958ea3, content=好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:18:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46309, encodeId=ee1246309d2, content=……, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Tue Dec 15 23:09:00 CST 2015, time=2015-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38768, encodeId=225138e6873, content=这篇文章写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Mon Oct 12 14:05:00 CST 2015, time=2015-10-12, status=1, ipAttribution=)]
    2015-10-12 hlycom3356

    这篇文章写的很好

    0

以上为热门评论，williamhill asia 医学App还有更多内容

相关威廉亚洲官网

Stroke：依折麦布（Ezetimibe）或逆转颈动脉斑块

　加拿大学者的一项研究表明，依折麦布似可逆转颈动脉粥样斑块负担。论文于2012年1月5日在线发表于《卒中》（Stroke）杂志。 　　目前对依折麦布未能减少颈动脉内中膜厚度存在争议。此项研究以在血管预防门诊内接受随访的患者为受试者，并对添加依折麦布的效果进行了分析；受试者均测定颈动脉粥样斑块负担（总斑块面积）用于指导治疗。 　　 结果显示，231例患者具有依折麦布治疗启动之前和之后2年的总斑块

NEJM：急性冠脉综合征后应用依折麦布-他汀类药物联合治疗

背景: 他汀类药物治疗可降低低密度脂蛋白（LDL）胆固醇水平与心血管事件的风险，但加入一种非他汀类药物依折麦布后，是否可以减少肠道胆固醇的吸收，以及进一步降低心血管事件发生率是未知的。    方法: 研究人员进行了这项涉及18144患者的双盲、随机试验，这些患者都曾在过去的10天内因急性冠脉综合征而入院，如果他们正在接受降脂治疗他们的LDL胆固醇水平为50-100mg

Diabetologia：依折麦布治疗非酒精性脂肪肝应慎重

单组临床试验研究和动物实验研究都表明，胆固醇吸收抑制剂依折麦布可有效改善非酒精性脂肪肝（NAFLD）的病理特征。然而，缺少关于这方面的随机对照试验数据。 为此，来自日本金泽大学的Takamura教授及其团队进行了一项随机对照开放临床试验，探讨依折麦布对NAFLD病理特征的影响。该研究结果发表在2014年05月的Diabetologia杂志上。 该研究计划招募80例患者，就像Takamura教授

FDA驳回阿托伐他汀/依折麦布复方片申请

 3月5日，FDA表示，暂时不会批准默克公司提交的低密度脂蛋白药物阿托伐他汀和依折麦布复方片新药申请（NDA）。FDA指出，经全面审查后，默克公司需要提交额外的数据，但没有明确是什么数据。默克公司发表声明称，其计划就该问题与FDA 进行进一步的沟通，他们将很快提交阿托伐他汀和依折麦布复方片的新数据。不同剂量的阿托伐他汀与依折麦布联合应用和阿托伐他汀/依折麦布单独应用试验研究正在进行中。